This Tiny U.K. Drugmaker Has Soared More Than 800% in Stock Rout
(Bloomberg) --
As the world scrambles to fight the deadly coronavirus, a microcap U.K. pharmaceutical company has seen its stock surge.
Shares in Synairgen Plc have soared 845% this year, with gains accelerating in mid-March after the company got approval from U.K. regulators to start trials of its drug, SNG001, in people hospitalized with Covid-19. The company has a market capitalization of just 67 million pounds ($83 million), even after the share-price jump.
SNG001 is a formulation of a naturally occurring protein, known as interferon beta, that Synairgen says may be deficient in those with greater susceptibility to the illness, such as the elderly or those with heart and lung complications or diabetes. The drug is administered via inhalation.
The company, which was founded by three university professors, said in a statement this week that the first patient in the Covid-19 trial had started treatment. It was already studying the drug in other pulmonary conditions. Initial data from the trial are expected in two months, with the timeframe for a product coming to market depending on the outcome of that data, Chief Executive Officer Richard Marsden said by phone.
The jump in Synairgen shares comes as investors -- and medical professionals -- stake hope and energy on finding ways to treat, track and prevent the coronavirus. While several small-cap biotech and health-care companies including iBio Inc., Novavax Inc. and BioCryst Pharmaceuticals Inc. have surged after saying they were working on treatments for the virus, getting drugs on the market is a notoriously tricky business and scientists have cautioned against finding a fast cure.
No Guarantee
The company's drug has “enormous” market potential, Finncap analyst Mark Brewer wrote in a March 26 research report. Brewer noted that the drug has previously proved beneficial in vitro -- in tests conducted outside of the human body -- against other coronaviruses, including Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS). The analyst's 120 pence price target implies the stock could almost double again from Wednesday's close. Finncap is also corporate broker to the company.
However, Peel Hunt analyst Anchal Verma, who doesn't have a rating on the stock, cautioned that while repurposed drugs may come with proven safety benefits, clear efficacy must still be established. “Outcomes of clinical trials are far from guaranteed,” she said.
Additionally, while the U.S. Food and Drugs Administration has committed to expediting the approval of treatments for coronavirus, it's not clear what degree of flexibility Synairgen will be allowed versus standard requirements, Verma added.
Interferon beta tamps down immune system activity and inflammation, and various versions of it are approved to treat multiple sclerosis, a disease where human immune cells attack the nervous system. The World Health Organization is coordinating the use of interferon beta, among other treatments, against coronavirus as part of its international Solidarity trial.
Synairgen sold 14 million pounds of new shares last week in order to fund SNG001 trials and manufacturing.
The company previously partnered with AstraZeneca Plc in 2014 to study SNG001 in severe asthma, but the trial was halted two years later after an interim analysis showed a very low number of reported severe exacerbations. The company also partners with Australia's Pharmaxis Ltd. on idiopathic pulmonary fibrosis treatment.
©2020 Bloomberg L.P.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.